RG Preclinical and Registry-Based Study Methodology

On the one hand, the working group focuses on the planning and analysis of preclinical studies, particularly animal studies. If you need assistance with this, please fill out the form. On the other hand, the working group has extensive experience in the planning, conduct, and analysis of registry studies with applications across a wide range of fields.

Lead

Michael Lauseker-Hao
PD Dr. Michael Lauseker-Hao

Lead of RG Preclinical and Registry-Based Study Methodology

Team

Jakub Fusiak, M.Sc.

Scientific researcher

Areas of work

The working group has extensive experience in conducting clinical and registry studies. Two large studies, BlastCrisis and PRiSMA, are currently underway; the working group helped design them and has been involved from the very beginning. Our involvement encompasses all aspects, from study design to statistical analysis. In addition to aspects of prognostic research that are of particular interest to us, these projects also focus on other issues such as quality of life and health services research.

Consulting on animal experiment proposals (including statistical reviews) is one of the working group’s core tasks. Improving the statistical quality of animal experiments is a key focus of this work.

The working group has many years of experience in prognostic research, particularly in the areas of chronic myeloid leukemia and myelodysplastic syndromes, as well as in epilepsy research. Most recently, a prognostic model for patients with CML in the blast phase was published

The research group’s methodological focus is on the analysis of event-time data, particularly competing events and multistage models.

Projects

Name of projectDescription
BlastCrisis / BlastPhase 2.0These two Europe-wide registry studies in the field of chronic myeloid leukemia focus on patients in the blast phase. The study is led by PD Dr. Annamaria Brioli (Hanover) and PD Dr. Michael Lauseker. Initial results have already been published: Development of a prognostic scoring system for chronic myeloid leukemia in blast phase, Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry.
PRiSMAThis registry focuses on pediatric stroke. Currently, centers from Germany, Austria, and Switzerland are participating. The study is led by PD Dr. Lucia Gerstl (LMU Medical Center); PD Dr. Michael Lauseker (responsible for data processing) and Jakob Fusiak are participating on behalf of the IBE. Details can be found here; the study protocol has already been published.
PROTAGORASThis multicenter, randomized, double-blind, placebo-controlled Phase III trial is evaluating whether heparin antagonism with protamine reduces post-procedural bleeding complications following TAVR without increasing the risk of ischemic events. The principal investigator is Prof. Dr. Massberg (LMU Medical Center); PD Dr. Michael Lauseker and Dr. Yujun Xu are participating on behalf of the IBE.
XVir-01This Phase I clinical dose-finding study is investigating the safety and tolerability of the oncolytic adenovirus XVir-N-31 for the treatment of patients with recurrent or refractory glioblastoma (WHO Grade IV). The study is led by Prof. Dr. Steinbach (Goethe University Frankfurt), and PD Dr. Michael Lauseker represents the IBE.
Epilepsy Prognosis ProjectAs part of a long-standing collaboration with PD Dr. Elisabeth Kaufmann (LMU Medical Center), prognostic factors in epilepsy are being investigated. This collaboration has resulted in numerous publications, including Who seizes longest? Impact of clinical and demographic factors and Longitudinal evaluation of retinal neuroaxonal loss in epilepsy using optical coherence tomography.
Prognosis for Myelodysplastic SyndromesAs part of a long-standing collaboration with Prof. Dr. Ulrich Germing (University of Düsseldorf), prognostic factors in myelodysplastic syndromes are being investigated. This collaboration has resulted in numerous publications, including The Absolute Monocyte Count at Diagnosis Affects Prognosis in Myelodysplastic Syndromes Independently of the IPSS-R Risk Score, In patients with myelodysplastic syndromes with del(5q), factors other than age and sex contribute to the prognostic advantage, which diminishes over time and Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study.